FDG PET for Dementia and Neurodegenerative Diseases

Medicare covers FDG PET to help distinguish Alzheimer disease from frontotemporal dementia in patients with a recent dementia diagnosis and documented cognitive decline of at least six months when diagnostic uncertainty remains after a comprehensive evaluation and other coverage requirements (accredited facility, expert reader, experienced diagnosing physician) are met. FDG PET is also covered only within CMS‑approved practical clinical trials for MCI or early dementia that meet specific protocol, IRB, and independent scientific review criteria; all other uses not specifically indicated by CMS remain noncovered.

"FDG PET is covered to aid differential diagnosis between Alzheimer disease (AD) and frontotemporal dementia (FTD) in patients with a recent diagnosis of dementia and documented cognitive decline of..."

Sign up to see full coverage criteria, indications, and limitations.